Trial: A Study of Disitamab Vedotin With Other…

Trial Details

Sponsor: Seagen, a wholly owned subsidiary of Pfizer (industry)

Phase: 2

Start date: May 20, 2024

Planned enrollment: 172

Trial ID: NCT06157892

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

More details:

This clinical trial is to evaluate disitamab vedotin in combination with tucatinib in subjects with LA/metastatic breast cancer or gastric cancer/GEJC that express HER2. The study has a dose escalation phase evaluating disitamab vedotin plus tucatinib followed by a dose optimization phase. The 2 dose levels identified in the dose escalation phase will be assessed in the optimization phase for both safety and efficacy in HER2-expressing LA/mBC and LA/mGC/GEJC. Once the safety and efficacy profile of disitamab vedotin plus tucatinib has been established and a disitamab vedotin dose with the optimum benefit/risk ratio has been determined the disitamab vedotin plus tucatinib combination therapy will be evaluated in an expansion phase with 4 expansion cohorts in subjects with HER2-low LA/mGC/GEJC, HER2+ LA/mGC/GEJC, HER2-low LA/mBC, and HER2+ LA/mBC.

Investigational Drug AI Analysis

Show for: disitamab vedotin (RC48, Aidixi)

Overview

Disitamab vedotin (DV; RC48; Aidixi) is a HER2‑directed antibody–drug conjugate (ADC) consisting of the humanized anti‑HER2 antibody hertuzumab linked via a protease‑cleavable mc‑val‑cit‑PABC linker to the microtubule inhibitor monomethyl auristatin E (MMAE). It has shown antitumor activity across multiple HER2‑expressing solid tumors, including urothelial, gastric/gastroesophageal junction (G/GEJ), and breast cancers. DV received its first approval in China in June 2021 for previously treated HER2‑overexpressing G/GEJ cancer. (pmc.ncbi.nlm.nih.gov)

Mechanism of action

Target: human epidermal growth factor receptor 2 (HER2). The hertuzumab antibody has high HER2 affinity and enhanced ADCC compared with trastuzumab in preclinical work. (ncbi.nlm.nih.gov)
Linker/payload: MMAE is attached via a cleavable maleimidocaproyl‑valine‑citrulline‑PABC linker (average drug‑to‑antibody ratio ≈4), enabling intracellular release after lysosomal protease cleavage. The cleavable linker confers a “bystander effect,” potentially benefiting heterogeneous HER2 expression. (pmc.ncbi.nlm.nih.gov)
Payload action: released MMAE disrupts microtubules, causing G2/M arrest and apoptosis. (pmc.ncbi.nlm.nih.gov)

Efficacy

Urothelial carcinoma (UC) - Phase II pooled analysis (RC48‑C005/C009; HER2‑positive la/mUC after ≥1 prior systemic therapy; n=107):
- ORR 50.5% (95% CI 40.6–60.3) by blinded independent review; median DoR 7.3 months; median PFS 5.9 months; median OS 14.2 months. Activity was seen across subgroups, including those with liver metastases and prior PD‑1/L1 therapy. (pubmed.ncbi.nlm.nih.gov) - Phase Ib/II combination with toripalimab (RC48‑C014; HER2‑unselected la/mUC; n=41; RP2D DV 2.0 mg/kg q2w + toripalimab 3 mg/kg q2w):
- Confirmed ORR 73.2%; median PFS 9.3 months; median OS 33.1 months (data cutoff March 1, 2024). (pubmed.ncbi.nlm.nih.gov) - Additional real‑world/retrospective data suggest clinically meaningful activity of DV plus PD‑1 inhibitors in metastatic upper tract UC, with ORR ~59% and median PFS ~13 months (limitations: retrospective design, China‑only cohorts). (pubmed.ncbi.nlm.nih.gov)

Gastric/gastroesophageal junction (G/GEJ) cancer - DV received its first approval in China (June 2021) for previously treated HER2‑overexpressing G/GEJ cancer. (pubmed.ncbi.nlm.nih.gov) - Early‑phase combination studies of DV with PD‑1 inhibitors have reported encouraging activity in HER2‑expressing G/GEJ disease (dose‑escalation/expansion study with toripalimab established RP2D of DV 2.5 mg/kg + toripalimab 3 mg/kg q2w; preliminary efficacy reported). (pubmed.ncbi.nlm.nih.gov) - A multicenter real‑world third‑line‑and‑beyond cohort showed higher ORR and longer PFS with DV plus immune checkpoint inhibitors versus DV alone in HER2‑positive or HER2‑low G/GEJ cancer (ORR 36% vs 10%; median PFS 6.2 vs 3.9 months). (bmccancer.biomedcentral.com)

Breast cancer - Phase I/Ib pooled analysis in advanced breast cancer (HER2‑overexpressing and HER2‑low): at the 2.0 mg/kg q2w dose, confirmed ORR was 42.9% in HER2‑overexpressing and 33.3% in HER2‑low cohorts; median PFS 5.7 and 5.1 months, respectively. (onlinelibrary.wiley.com) - Retrospective real‑world series in previously trastuzumab‑treated metastatic HER2‑positive disease reported ORR 29.6% and median real‑world PFS 5.9 months. (pubmed.ncbi.nlm.nih.gov)

Safety

Across trials, the most frequent treatment‑related adverse events (TRAEs) include peripheral sensory neuropathy, hematologic toxicity (neutropenia, leukopenia), and transaminase elevations—generally consistent with MMAE‑based ADCs. In the pooled phase II UC analysis, any‑grade peripheral sensory neuropathy occurred in 68.2% (grade ≥3 in 18.7%); leukopenia in 50.5%; neutropenia in 42.1%. (pubmed.ncbi.nlm.nih.gov)

With DV plus toripalimab in la/mUC (RC48‑C014), common TRAEs were AST increased (65.9%), ALT increased (63.4%), and peripheral sensory neuropathy (63.4%); grade ≥3 TRAEs occurred in 51.2%, and one treatment‑related death (pneumonitis) was reported. (pubmed.ncbi.nlm.nih.gov)

In the phase I/Ib breast cancer program, grade ≥3 events ≥5% included decreased neutrophil count (17.6%), GGT increased (13.2%), asthenia (11.0%), decreased WBC (9.6%); neuropathy events were observed but severe neurotoxicity was uncommon. (onlinelibrary.wiley.com)

HealthScout AI Analysis

Goal: Evaluate the safety, tolerability, dose, and preliminary antitumor activity of disitamab vedotin in combination with tucatinib in HER2-expressing solid tumors, specifically locally advanced or metastatic breast cancer and gastric/gastroesophageal junction adenocarcinoma, and determine an optimal dose for further study before expanding into defined HER2-low and HER2-positive cohorts.

Patients: Adults with measurable, locally advanced unresectable or metastatic breast cancer or gastric/GEJ adenocarcinoma with HER2 expression, ECOG 0–1, and prior progression on or intolerance to standard therapies. Expansion cohorts enroll HER2-low (IHC 1+ or 2+/ISH−) and HER2-positive (IHC 3+ or 2+/ISH+) subtypes in both breast and gastric/GEJ cancers. Key exclusions include prior tucatinib, prior ADCs with an MMAE payload, active CNS or leptomeningeal disease, recent anticancer therapy within 4 weeks, and conditions precluding oral absorption.

Design: Phase 1b/2, open-label, multicenter study with sequential parts: dose escalation of disitamab vedotin plus tucatinib, followed by a randomized dose-optimization phase assessing two DV dose levels for safety and efficacy in HER2-expressing breast and gastric/GEJ cancers, then expansion into four cohorts (HER2-low and HER2-positive for both tumor types). Planned enrollment is 172 participants.

Treatments: Disitamab vedotin plus tucatinib in all phases and cohorts. Disitamab vedotin (RC48) is an anti-HER2 antibody-drug conjugate comprising a humanized anti-HER2 antibody linked via a cleavable vedotin linker to the microtubule inhibitor MMAE. Mechanisms include targeted delivery to HER2-expressing cells, bystander killing, immunogenic cell death, and HER2 signaling inhibition. Clinical data to date show activity across HER2-overexpressing and HER2-low tumors, including objective responses in metastatic breast cancer and approved use in China for HER2-overexpressing gastric cancer after at least two prior lines; common toxicities include peripheral neuropathy, cytopenias, transaminitis, and fatigue. Tucatinib is an orally administered, selective HER2 tyrosine kinase inhibitor approved in combination regimens for HER2-positive breast cancer, including in patients with brain metastases.

Outcomes: Primary: safety and tolerability measures including laboratory abnormalities, adverse events, dose-limiting toxicities in escalation, and frequency of dose modifications; objective response rate by investigator per RECIST v1.1 in later phases. Secondary: duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics (Cmax, AUClast), and incidence of anti-drug antibodies to disitamab vedotin.

Burden on patient: Moderate to high. As a Phase 1b/2 combination study with dose escalation and pharmacokinetics, participants can expect intensive early-cycle visits with frequent labs, AE monitoring, and serial PK blood draws. Imaging per RECIST at regular intervals will require travel for scans. Disitamab vedotin is administered intravenously, adding infusion time and potential premedications, while tucatinib is oral and requires adherence and monitoring for hepatic toxicity and diarrhea. Some cohorts require provision of archival or new tumor tissue, which may necessitate a biopsy if archival tissue is insufficient. The open-label design and multi-year follow-up for survival and safety extend visit frequency and monitoring beyond standard care in later lines of therapy.

Last updated: Oct 2025

Eligibility

Show Criteria

Inclusion Criteria:

General Inclusion Criteria

* Measurable disease according to RECIST v1.1

* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

Dose Escalation and Optimization Phase Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma or breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* Must have experienced disease progression on or after standard of care therapies or be intolerant of standard of care therapies.

Cohort A (HER2-Low Breast Cancer) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2-low status determined by most recent local assessment (IHC 1+ or IHC 2+/ISH-negative)

* Prior therapies requirements

* No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC.

* Participants with known BRCA mutation must have received a PARP-inhibitor where available and not medically contraindicated

* Have progression on or after, or intolerant to, T-DXd, sacituzumab govitecan, or other topoisomerase I inhibitor therapies, if available as local standard of care therapy

* Participants with HR+ tumors must have intolerance to endocrine therapy or endocrine therapy refractory disease:

* Progressed on ≥2 lines of endocrine therapy for LA/mBC AND had received a CDK4/6 inhibitor in the adjuvant or metastatic setting OR

* Progressed on 1 line of endocrine therapy for LA/mBC AND had a relapse while on adjuvant endocrine therapy after definitive surgery for primary tumor AND had received a CDK4/6 inhibitor in the adjuvant or advanced setting

* Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab with chemotherapy if available as local standard of care therapy.

* Participants with HR negative, HER2-low and PD-L1-positive (CPS 10 or greater) tumors must have received pembrolizumab (or other PD-(L)1 inhibitor) with chemotherapy if available as local standard of care therapy and not medically contraindicated.

Cohort B (HER2+ Breast Cancer) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis breast carcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)

* Participants must have:

* Received prior trastuzumab, pertuzumab and a taxane if available as local standard of care therapy for advanced disease.

* Have progression on or after, or intolerant to, T-DXd or other topoisomerase I inhibitor therapies

* No more than 3 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mBC

Cohort C (HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2-low expression defined as IHC 1+ or IHC 2+/ISH-negative determined by most recent local assessment

* Willing and able to provide archival or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks

* Participants must have received:

* Prior systemic therapy with platinum, fluorouracil, or taxane for locally advanced unresectable or metastatic disease

* Progression within 6 months of last dose of (neo)adjuvant cytotoxic chemotherapy is considered as 1 line of systemic therapy for LA/mGC/GEJC

* Prior anti-PD-(L)1 therapy is allowed

* No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADC) for LA/mGC/GEJC

* Must not have received prior treatment with HER2 directed therapy

Cohort D (HER2+ LA/mGC/GEJC) Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma

* Locally-advanced, unresectable, or metastatic stage

* HER2+ status determined by most recent local assessment (IHC 3+ or IHC 2+/ISH+)

* Participants must have:

* Received prior trastuzumab plus fluoropyrimidine and platinum containing chemotherapy if no contraindication.

* Prior T-DXd treatment is allowed

* Prior PD1 inhibitor therapy is allowed

* No more than 2 prior systemic cytotoxic chemotherapy regimens (including ADCs) for LA/mGC/GEJC

Exclusion Criteria:

* Known hypersensitivity to any excipient contained in the drug formulation of disitamab vedotin or tucatinib

* Prior therapy with ADCs with MMAE payload

* Prior therapy with tucatinib

* Active CNS and/or leptomeningeal metastasis.

* Participants who have received prior systemic anticancer treatment including investigational agents within 4 weeks prior to first dose of study treatment

* History of other invasive malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.

* Unable to swallow oral tablets or capsules or any significant GI disease which would preclude the adequate oral absorption of medications

Sites (125)

Sort by distance to:

BC Cancer Kelowna.

Kelowna, British Columbia, V1Y 5L3, Canada

No email / No phone

Status: Recruiting

Ottawa Hospital Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada

No email / No phone

Status: Recruiting

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

No email / No phone

Status: Recruiting

University Health Network, Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

No email / No phone

Status: Recruiting

Klinikums rechts der Isar der TU München

München, 81675, Germany

No email / No phone

Status: Recruiting

Universitatsklinikum Essen

Essen, 45147, Germany

No email / No phone

Status: Recruiting

Universitatsklinikum Heidelberg

Heidelberg, 69120, Germany

No email / No phone

Status: Recruiting

Istituto Europeo di Oncologia

Milan, Lombardy, 20141, Italy

No email / No phone

Status: Recruiting

Korea University Anam Hospital

Seoul, 02841, South Korea

No email / No phone

Status: Recruiting

Seoul National University Bundang Hospital

Seongnam-si, 463-707, South Korea

No email / No phone

Status: Recruiting

Severance Hospital Yonsei University Health System

Seoul, 3722, South Korea

No email / No phone

Status: Recruiting

National Cancer Center

Goyang-si, Other, 10408, South Korea

No email / No phone

Status: Recruiting

CETIR Grup Medic

Barcelona, 08950, Spain

No email / No phone

Status: Recruiting

Ecg Medica Sl

Valencia, 46004, Spain

No email / No phone

Status: Recruiting

Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid

Madrid, 28050, Spain

No email / No phone

Status: Recruiting

Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain

No email / No phone

Status: Recruiting

Hospital Universitari Vall d´Hebron

Barcelona, 08035, Spain

No email / No phone

Status: Recruiting

L'Institut Catala d'Oncologia.

L'Hospitalet de Llobregat, 08908, Spain

No email / No phone

Status: Recruiting

Quirén Salud Barcelona

Barcelona, 08023, Spain

No email / No phone

Status: Recruiting

START Madrid-CIOCC_Hospital HM Sanchinarro

Madrid, 28050, Spain

No email / No phone

Status: Recruiting

The Royal Marsden Hospital

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

The Royal Marsden NHS Foundation Trust (RM)

London, SW3 6JJ, United Kingdom

No email / No phone

Status: Recruiting

The Royal Marsden Hospital

Sutton, Surrey, SM2 5PT, United Kingdom

No email / No phone

Status: Recruiting

Banner-University Medical Center Tucson Campus

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Banner-University Medical Center Tucson Campus

Tucson, Arizona, 85704, United States

No email / No phone

Status: Recruiting

The University of Arizona Cancer Center-Main

Tucson, Arizona, 85724, United States

No email / No phone

Status: Recruiting

The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

University of Arizona Cancer Center - North Campus

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Chao Family Comprehensive Cancer Center University of California Irvine

Orange, California, 92868, United States

No email / No phone

Status: Recruiting

UC Irvine Medical Center

Orange, California, 92868, United States

No email / No phone

Status: Recruiting

UCLA Department of Medicine - Hematology & Oncology

Santa Monica, California, 90504, United States

No email / No phone

Status: Recruiting

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

San Francisco, California, 94158, United States

No email / No phone

Status: Recruiting

Colorado West Healthcare System, dba Community Hospital

Grand Junction, Colorado, 81505, United States

No email / No phone

Status: Recruiting

Colorado West Healthcare, dba Grand Valley Oncology

Grand Junction, Colorado, 81505, United States

No email / No phone

Status: Recruiting

Danbury Hospital

Danbury, Connecticut, 06810, United States

No email / No phone

Status: Recruiting

The Whittingham Cancer Center / Norwalk Hospital

Norwalk, Connecticut, 06856, United States

No email / No phone

Status: Recruiting

Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States

No email / No phone

Status: Recruiting

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States

No email / No phone

Status: Recruiting

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center - International Plaza

Tampa, Florida, 33607, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Moffitt Cancer Center at Wesley Chapel

Wesley Chapel, Florida, 33544, United States

No email / No phone

Status: Recruiting

Moffitt McKinley Hospital

Tampa, Florida, 33612, United States

No email / No phone

Status: Recruiting

Atlanta Cancer Care - Atlanta

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Atlanta Cancer Care - Cumming

Cumming, Georgia, 30041, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Annex

Atlanta, Georgia, 30341, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Athens

Athens, Georgia, 30606, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Blairsville

Blairsville, Georgia, 30512, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Canton

Canton, Georgia, 30115, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Cumming

Cumming, Georgia, 30041, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Decatur

Decatur, Georgia, 30033, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Macon

Macon, Georgia, 31217, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists - Marietta

Marietta, Georgia, 30060, United States

No email / No phone

Status: Recruiting

Georgia Cancer Specialists-Northside

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Northside Hospital

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Northside Hospital, Inc.- Central Research Department

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Recruiting

Suburban Hematology-Oncology Associates - Duluth

Duluth, Georgia, 30096, United States

No email / No phone

Status: Recruiting

Suburban Hematology-Oncology Associates- Lawrenceville

Lawrenceville, Georgia, 30046, United States

No email / No phone

Status: Recruiting

Memorial Hospital

Shiloh, Illinois, 62269, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - Shiloh

Shiloh, Illinois, 62269, United States

No email / No phone

Status: Recruiting

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute- Chestnut Hill

Newton, Massachusetts, 02459, United States

No email / No phone

Status: Recruiting

Massachusetts General Hospital.

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Barnes-Jewish Hospital

St Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Saint Luke's Cancer Institute LLC

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Saint Luke's Hospital Investigational Pharmacy

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - North County

Florissant, Missouri, 63031, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - South County

St Louis, Missouri, 63129, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - St Peters

City of Saint Peters, Missouri, 63376, United States

No email / No phone

Status: Recruiting

Siteman Cancer Center - West County

Creve Coeur, Missouri, 63141, United States

No email / No phone

Status: Recruiting

St Lukes Hospital

Kansas City, Missouri, 64111, United States

No email / No phone

Status: Recruiting

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Washington University in St Louis.

St Louis, Missouri, 63110, United States

No email / No phone

Status: Recruiting

Renown Regional Medical Center

Reno, Nevada, 89502, United States

No email / No phone

Status: Recruiting

Memorial Sloan Kettering Cancer Center - Main Hospital

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Zangmeister Cancer Center

Columbus, Ohio, 43219, United States

No email / No phone

Status: Recruiting

Saint Francis Hospital / Bon Secours - South Carolina

Greenville, South Carolina, 29607, United States

No email / No phone

Status: Recruiting

SCRI Oncology Partners

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

Tennessee Oncology-Nashville/Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

Parkland Health and Hospital System

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center - Simmons Cancer Center

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Clinical Lab-Zale Lipshy University Hospital

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Simmons Cancer Center - Redbird

Dallas, Texas, 75237, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center Simmons Cancer Center - Richardson/Plano

Richardson, Texas, 75080, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center-Simmons Cancer Center Pharmacy

Dallas, Texas, 75235, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

University of Texas Southwestern Simmons Cancer Center - Fort Worth

Fort Worth, Texas, 76104, United States

No email / No phone

Status: Recruiting

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington

Seattle, Washington, 98109, United States

No email / No phone

Status: Recruiting

Harborview Medical Center

Seattle, Washington, 98104, United States

No email / No phone

Status: Recruiting

University of Washington Medical Center

Seattle, Washington, 98195, United States

No email / No phone

Status: Recruiting

Carbone Cancer Center / University of Wisconsin

Madison, Wisconsin, 53792, United States

No email / No phone

Status: Recruiting

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718, United States

No email / No phone

Status: Recruiting

Peninsula & South Eastern Hematology and Oncology Group (PASO)

Frankston, Australia

No email / No phone

Status: Not yet recruiting

Peninsula & South Eastern Hematology and Oncology Group (PASO)

Frankston, Victoria, 3199, Australia

No email / No phone

Status: Not yet recruiting

Slade Health

Mount Waverley, Victoria, 3149, Australia

No email / No phone

Status: Not yet recruiting

Slade Pharmacy Frankston

Frankston, Victoria, 3199, Australia

No email / No phone

Status: Not yet recruiting

Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF)

Berlin, 12203, Germany

No email / No phone

Status: Not yet recruiting

A.O.U. Federico II- U.O.C. Diagnostica per lmmagini e Radioterapia

Napoli, 80131, Italy

No email / No phone

Status: Not yet recruiting

A.O.U. Federico II

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Azienda Ospedaliera Universitaria (AOU) Federico II

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale.

Napoli, Campania, 80131, Italy

No email / No phone

Status: Not yet recruiting

Niguarda Ca' Granda Hospital

Milan, Lombardy, 20162, Italy

No email / No phone

Status: Not yet recruiting

Humanitas Istituto Clinico Catanese

Misterbianco (CT), Sicily, 95045, Italy

No email / No phone

Status: Not yet recruiting

Azienda Ospedaliera Universitaria Integrata di Verona.

Verona, Veneto, 37134, Italy

No email / No phone

Status: Not yet recruiting

Chungbuk National University Hospital

Cheongju-si, 28644, South Korea

No email / No phone

Status: Not yet recruiting

Gachon University Gil Medical Center

Incheon, 21565, South Korea

No email / No phone

Status: Not yet recruiting

Samsung Medical Center

Seoul, 06351, South Korea

No email / No phone

Status: Not yet recruiting

Seoul National University Hospital

Seoul, 110-744, South Korea

No email / No phone

Status: Not yet recruiting

St. Vincent's Hospital, The Catholic University of Korea

Suwon, 16247, South Korea

No email / No phone

Status: Not yet recruiting

Dong-A University Hospital

Busan, Other, 49201, South Korea

No email / No phone

Status: Not yet recruiting

Grupo Hospitalario QuironSalud

Erandio Bizkaia, 48950, Spain

No email / No phone

Status: Not yet recruiting

Hospital Universitario de Basurto

Bilbao, 48013, Spain

No email / No phone

Status: Not yet recruiting

Linkou Chang Gung Memorial Hospital

Taoyuan, 333, Taiwan

No email / No phone

Status: Not yet recruiting

National Cheng Kung University Hospital

Tainan City, 704017, Taiwan

No email / No phone

Status: Not yet recruiting

National Cheng Kung University Hospital

Tainan City, 704, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Cancer Center

Taipei, 106, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Hospital

Taipei, 100225, Taiwan

No email / No phone

Status: Not yet recruiting

National Taiwan University Hospital

Taipei, 100, Taiwan

No email / No phone

Status: Not yet recruiting

St Bartholomew's Hospital

London, EC1M 6BQ, United Kingdom

No email / No phone

Status: Not yet recruiting

The Christie NHS Foundation Trust

Manchester, M20 4GJ, United Kingdom

No email / No phone

Status: Not yet recruiting

The Royal Marsden NHS Foundation Trust

Sutton, SM2 5PT, United Kingdom

No email / No phone

Status: Not yet recruiting

San Juan Oncology Associates

Farmington, New Mexico, 87401, United States

No email / No phone

Status: TERMINATED

A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: disitamab vedotin (RC48, Aidixi)

Overview

Mechanism of action

Efficacy

Safety

Further reading

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (125)

BC Cancer Kelowna.

Ottawa Hospital Cancer Centre

Sunnybrook Health Sciences Centre

University Health Network, Princess Margaret Hospital

Klinikums rechts der Isar der TU München

Universitatsklinikum Essen

Universitatsklinikum Heidelberg

Istituto Europeo di Oncologia

Korea University Anam Hospital

Seoul National University Bundang Hospital

Severance Hospital Yonsei University Health System

National Cancer Center

CETIR Grup Medic

Ecg Medica Sl

Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid

Hospital Clinico Universitario de Valencia

Hospital Universitari Vall d´Hebron

L'Institut Catala d'Oncologia.

Quirén Salud Barcelona

START Madrid-CIOCC_Hospital HM Sanchinarro

The Royal Marsden Hospital

The Royal Marsden NHS Foundation Trust (RM)

The Royal Marsden Hospital

Banner-University Medical Center Tucson Campus

Banner-University Medical Center Tucson Campus

The University of Arizona Cancer Center-Main

The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal

University of Arizona Cancer Center - North Campus

Chao Family Comprehensive Cancer Center University of California Irvine

UC Irvine Medical Center

UCLA Department of Medicine - Hematology & Oncology

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies

Colorado West Healthcare System, dba Community Hospital

Colorado West Healthcare, dba Grand Valley Oncology

Danbury Hospital

The Whittingham Cancer Center / Norwalk Hospital

Georgetown University Medical Center

MedStar Georgetown University Hospital

H. Lee Moffitt Cancer Center and Research Institute

Moffitt Cancer Center - International Plaza

Moffitt Cancer Center - McKinley Campus

Moffitt Cancer Center at Wesley Chapel

Moffitt McKinley Hospital

Atlanta Cancer Care - Atlanta

Atlanta Cancer Care - Cumming

Georgia Cancer Specialists - Annex

Georgia Cancer Specialists - Athens

Georgia Cancer Specialists - Blairsville

Georgia Cancer Specialists - Canton

Georgia Cancer Specialists - Cumming

Georgia Cancer Specialists - Decatur

Georgia Cancer Specialists - Macon

Georgia Cancer Specialists - Marietta

Georgia Cancer Specialists-Northside

Northside Hospital

Northside Hospital, Inc.- Central Research Department

Suburban Hematology-Oncology Associates - Duluth

Suburban Hematology-Oncology Associates- Lawrenceville

Memorial Hospital

Siteman Cancer Center - Shiloh

Brigham and Women's Hospital

Dana Farber Cancer Institute

Dana Farber Cancer Institute- Chestnut Hill

Massachusetts General Hospital.

Barnes-Jewish Hospital